Sign in Subscribe
Cancer research

Novel Combination Therapy Shows Promise in Treating Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

Researchers at Zunyi Medical University have made significant progress in the development of a novel combination therapy for treating non-small cell lung cancer (NSCLC). The study, published in Technology in Cancer Research & Treatment, investigated the efficacy and safety of combining anti-angiogenic agents, such as recombinant human vascular endothelial inhibitor (endostar), with immune checkpoint inhibitors (ICIs) and chemotherapy. This combination therapy has shown promising results in improving progression-free survival (PFS) and overall survival (OS) in patients with advanced squamous NSCLC.

Key Takeaways:

  • The study was funded by the Future Science And Technology Elite Talent Cultivation Project of Zunyi Medical University, The Natural Science Foundation of Guizhou Province, and other organizations.
  • The combination therapy involved the use of endostar, sintilimab, and chemotherapy in advanced sq-NSCLC patients.
  • The primary endpoint was PFS, with secondary endpoints including OS, duration of response (DoR), disease control rate (DCR), and safety.
  • The study enrolled 64 patients with advanced sq-NSCLC and negative driver gene mutations.
  • Radiological assessments were performed every 8 weeks initially, then every 12 weeks.
  • Biomarker analysis and quality of life assessments were also performed.

Statistics:

  • The study was a prospective, single-arm, multicenter phase II trial (NCT06746179).
  • 64 patients were enrolled in the study.
  • Patients received endostar (210 mg/dose, 72 h), sintilimab (200 mg/dose), and chemotherapy (nab-PP, carboplatin/cisplatin + albumin-bound paclitaxel) every 3 weeks for up to 6 cycles.
  • Maintenance therapy was continued until progression or intolerable toxicity occurred.

Sources:

  • NewsRx. Studies from Zunyi Add New Findings in the Area of Non-Small Cell Lung Cancer (Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell ...). Immunotherapy Weekly. June 11, 2025; p 7062.
  • Sintilimab + Nab-PP Combined with Recombinant Human Vascular Endothelial Inhibitor for Locally Advanced/Advanced and Recurrent Metastatic Squamous Non-Small Cell Lung Cancer: Study Protocol for a Single-Arm, Multi-Centre Phase II Clinical Study. Technology in Cancer Research & Treatment, 2025, 24.
  • Technology in Cancer Research & Treatment, SAGE Publishing.

Read more